These compounds may interact with:
Ephrin type-B receptor 4
Potentially involved in: kidney cancer; carcinoma; cancer; mammary neoplasms; tetralogy of fallot; amyotrophic lateral sclerosis; atypical teratoid / rhabdoid tumor; intraductal papillary-mucinous carcinoma (ipmc); juvenile dermatomyositis; lung carcinoma; ovarian cancer; psoriasis; sonic hedgehog group medulloblastoma; breast neoplasms; hydrops fetalis, nonimmune, and/or atrial septal defect, susceptibility to; philadelphia chromosome positive chronic myelocytic leukemia; philadelphia chromosome-positive acute lymphoblastic leukemia; blastic phase chronic myeloid leukemia; chronic phase chronic myeloid leukemia; chronic myelocytic leukemia accelerated phase
Disease data sourced from Pharos.